Therapy Detail

Therapy Name Capmatinib
Therapy Description

Capmatinib (INC280) inhibits c-MET and may induce cell death in tumors over expressing c-MET or expressing constitutively activated c-MET (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Capmatinib INC280 MET Inhibitor 50 Capmatinib (INC280) inhibits c-MET and may induce cell death in tumors over expressing c-MET or expressing constitutively activated c-MET (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
MET del exon14 lung squamous cell carcinoma sensitive Capmatinib Clinical Study Actionable In a clinical case study, Capmatinib (INC280) treatment resulted in a decreased tumor volume of 61% in a patient with lung squamous cell carcinoma harboring a deletion of MET exon 14 (PMID: 25971938). 25971938
MET Y1230C stomach cancer resistant Capmatinib Preclinical - Cell culture Actionable In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) treated with Capmatinib (INC280) in culture for several months developed resistance and was found to harbor MET Y1230C (PMID: 28765324). 15494073 28765324
MET F1200L MET Y1230H stomach cancer resistant Capmatinib Preclinical - Cell culture Actionable In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) co-harboring MET Y1230H and MET F1200L demonstrated resistance when treated with Capmatinib (INC280) in culture (PMID: 28765324). 28765324 15494073
MET D1228N Advanced Solid Tumor predicted - resistant Capmatinib Preclinical Actionable In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to MET D1228N in humans) were resistant to treatment with Capmatinib (INC280), demonstrating sustained cell growth in culture and minimal tumor growth inhibition in mouse models (PMID: 28396313). 28396313
MET exon 14 non-small cell lung carcinoma sensitive Capmatinib Phase I Actionable In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 100% (2/2) of non-small cell lung carcinoma patients harboring MET exon 14 mutations (J Clin Oncol 34, 2016 (suppl; abstr 9067)). detail...
MET del exon14 TP53 N30fs lung large cell carcinoma sensitive Capmatinib Clinical Study Actionable In a clinical case study, Capmatinib (INC280) treatment resulted in decreased tumor volume by 53% in a patient with large cell lung carcinoma harboring MET deletion exon 14 and TP53 N30fs*14 (PMID: 25971938). 25971938
MET amp Advanced Solid Tumor predicted - sensitive Capmatinib Phase I Actionable In a Phase I trial, INC280 displayed safety and preliminary efficacy in patients with MET dependent solid tumors (J Clin Oncol 32:5s, 2014 (suppl; abstr 2520)). detail...
MET amp non-small cell lung carcinoma sensitive Capmatinib Phase I Actionable In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 63% (5/8) of MET amplified non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)). detail...
MET Y1230H Advanced Solid Tumor predicted - resistant Capmatinib Preclinical Actionable In a preclinical study, transformed cells expressing mouse MET Y1228H (corresponds to MET Y1230H in humans) were resistant to treatment with Capmatinib (INC280), demonstrating sustained cell growth in culture and minimal tumor growth inhibition in mouse models (PMID: 28396313). 28396313
MET D1228V Advanced Solid Tumor resistant Capmatinib Preclinical - Cell culture Actionable In a preclinical study, transformed human cells expressing MET D1228V demonstrated resistance to treatment with Capmatinib (INC280) in culture, resulting in sustained Met phosphorylation (PMID: 27694386). 27694386
MET del exon14 Advanced Solid Tumor sensitive Capmatinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing MET deletion exon 14 were sensitive to Capmatinib (INC280) treatment in culture, demonstrating inhibition of spheroid growth (PMID: 28765324). 28765324
MET positive non-small cell lung carcinoma sensitive Capmatinib Phase I Actionable In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 19% (5/26) of MET-positive non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02626234 Phase I Capmatinib A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors Completed
NCT02414139 Phase II Capmatinib Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With Advanced Non-small Cell Lung Cancer Who Have Received One or Two Prior Lines of Therapy Recruiting
NCT01324479 Phase I Capmatinib Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors Completed
NCT02750215 Phase II Capmatinib A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor Recruiting
NCT03040973 FDA approved Capmatinib Roll-over Study for Patients With cMET-dependent Malignancies Who Previously Completed a Novartis Capmatinib Study Recruiting
NCT02925104 Phase I Capmatinib A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors. Completed
NCT02019693 Phase II Capmatinib A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer Recruiting
NCT02520752 Phase I Midazolam Capmatinib A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors Completed
NCT02587650 Ceritinib Capmatinib Regorafenib Entrectinib Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma Recruiting
NCT02468661 Phase Ib/II Capmatinib Erlotinib Cisplatin + Pemetrexed Carboplatin + Pemetrexed A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification Recruiting